Literature DB >> 23064699

Green tea epigallocatechin-3-gallate modulates differentiation of naïve CD4⁺ T cells into specific lineage effector cells.

Junpeng Wang1, Munkyong Pae, Simin Nikbin Meydani, Dayong Wu.   

Abstract

CD4(+) T helper (Th) subsets Th1, Th9, and Th17 cells are implicated in inducing autoimmunity whereas regulatory T cells (Treg) have a protective effect. We and others have previously shown that epigallocatechin-3-gallate (EGCG) attenuates experimental autoimmune encephalomyelitis (EAE) and alters CD4(+) T cell subpopulations. In this study, we investigated how EGCG impacts differentiation of naïve CD4(+) T cells into different effector lineages and report that EGCG impeded Th1, Th9, and Th17 differentiation and prevented IL-6-induced suppression of Treg development. We further showed that EGCG inhibited T-bet, PU.1, and RORγt, the specific transcription factors for Th1, Th9, and Th17 differentiation, respectively. These effects, in turn, may be mediated by EGCG-induced downregulation of transducers p-STAT1 and p-STAT4 for Th1, and p-STAT3 for Th17. EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3. This notion was further supported by the in vivo results showing inhibited IL-6 and soluble IL-6R but increased soluble gp130 levels in plasma from EAE mice fed EGCG. Together, our results suggest that EGCG modulates development of CD4(+) T cell lineages through impacting their respective and interactive regulatory networks ultimately leading to an attenuated autoimmune response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23064699     DOI: 10.1007/s00109-012-0964-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  45 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease.

Authors:  Kevin Gillespie; Isamu Kodani; Douglas P Dickinson; Kalu U E Ogbureke; Amy M Camba; Mengjie Wu; Stephen Looney; Tin-Chun Chu; Haiyan Qin; Frederick Bisch; Mohamed Sharawy; George S Schuster; Stephen D Hsu
Journal:  Life Sci       Date:  2008-09-06       Impact factor: 5.037

3.  Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea.

Authors:  T M Haqqi; D D Anthony; S Gupta; N Ahmad; M S Lee; G K Kumar; H Mukhtar
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 4.  Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors.

Authors:  Jinfang Zhu; William E Paul
Journal:  Immunol Rev       Date:  2010-11       Impact factor: 12.988

5.  Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis.

Authors:  Orhan Aktas; Timour Prozorovski; Alina Smorodchenko; Nicolai E Savaskan; Roland Lauster; Peter-Michael Kloetzel; Carmen Infante-Duarte; Stefan Brocke; Frauke Zipp
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

6.  Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population.

Authors:  Hongmei Li; Bardia Nourbakhsh; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

7.  The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation.

Authors:  Hua-Chen Chang; Sarita Sehra; Ritobrata Goswami; Weiguo Yao; Qing Yu; Gretta L Stritesky; Rukhsana Jabeen; Carl McKinley; Ayele-Nati Ahyi; Ling Han; Evelyn T Nguyen; Michael J Robertson; Narayanan B Perumal; Robert S Tepper; Stephen L Nutt; Mark H Kaplan
Journal:  Nat Immunol       Date:  2010-05-02       Impact factor: 25.606

8.  Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation.

Authors:  Katja Herges; Jason M Millward; Nicole Hentschel; Carmen Infante-Duarte; Orhan Aktas; Frauke Zipp
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

9.  IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells.

Authors:  Valérie Dardalhon; Amit Awasthi; Hyoung Kwon; George Galileos; Wenda Gao; Raymond A Sobel; Meike Mitsdoerffer; Terry B Strom; Wassim Elyaman; I-Cheng Ho; Samia Khoury; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2008-11-09       Impact factor: 25.606

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  18 in total

Review 1.  Emerging targets in lipid-based therapy.

Authors:  Stephanie C Tucker; Kenneth V Honn
Journal:  Biochem Pharmacol       Date:  2012-12-20       Impact factor: 5.858

2.  Epigallocatechin-3-gallate-induced inhibition of interleukin-6 release and adjustment of the regulatory T/T helper 17 cell balance in the treatment of colitis in mice.

Authors:  Zhenglei Xu; Cheng Wei; R U Zhang; Jun Yao; Dinguo Zhang; Lisheng Wang
Journal:  Exp Ther Med       Date:  2015-10-23       Impact factor: 2.447

3.  Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1.

Authors:  Antonia Janssen; Sebastian Fiebiger; Helena Bros; Laura Hertwig; Silvina Romero-Suarez; Isabell Hamann; Coralie Chanvillard; Judith Bellmann-Strobl; Friedemann Paul; Jason M Millward; Carmen Infante-Duarte
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

4.  Epigenetic activities of flavonoids in the prevention and treatment of cancer.

Authors:  Christian Busch; Markus Burkard; Christian Leischner; Ulrich M Lauer; Jan Frank; Sascha Venturelli
Journal:  Clin Epigenetics       Date:  2015-07-10       Impact factor: 6.551

Review 5.  Cancer microenvironment, inflammation and cancer stem cells: A hypothesis for a paradigm change and new targets in cancer control.

Authors:  Russell L Blaylock
Journal:  Surg Neurol Int       Date:  2015-05-29

6.  Th9/IL-9 profile in human echinococcosis: their involvement in immune response during infection by Echinococcus granulosus.

Authors:  Nannan Pang; Fengbo Zhang; Xiumin Ma; Zhaoxia Zhang; Hui Zhao; Yan Xin; Song Wang; Yuejie Zhu; Hao Wen; Jianbing Ding
Journal:  Mediators Inflamm       Date:  2014-03-30       Impact factor: 4.711

7.  BJ-3105, a 6-Alkoxypyridin-3-ol Analog, Impairs T Cell Differentiation and Prevents Experimental Autoimmune Encephalomyelitis Disease Progression.

Authors:  Maheshwor Timilshina; Youra Kang; Ishmit Dahal; Zhiwei You; Tae-Gyu Nam; Keuk-Jun Kim; Byeong-Seon Jeong; Jae-Hoon Chang
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

8.  Naringenin Modifies the Development of Lineage-Specific Effector CD4+ T Cells.

Authors:  Junpeng Wang; Xinli Niu; Chunfang Wu; Dayong Wu
Journal:  Front Immunol       Date:  2018-10-01       Impact factor: 7.561

Review 9.  Modulation of immune function by polyphenols: possible contribution of epigenetic factors.

Authors:  Alejandro Cuevas; Nicolás Saavedra; Luis A Salazar; Dulcineia S P Abdalla
Journal:  Nutrients       Date:  2013-06-28       Impact factor: 5.717

10.  Clinical effects of soluble interleukin-6 receptor detection on autoimmune rheumatic disease patients.

Authors:  Meng Chen; Ming-Hua Xu; Cai-Xia Sun; Zheng Zhang; Yong Du
Journal:  Pak J Med Sci       Date:  2014-07       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.